U.S. Markets open in 1 hr 36 mins

Lilly to seek FDA approval for Alzheimer's drug this year

In this article:
  • Oops!
    Something went wrong.
    Please try again later.

June 24 (Reuters) - Eli Lilly and Co said on Thursday it will file marketing application for its experimental Alzheimer's drug, donanemab, under the U.S. health regulator's accelerated approval pathway later this year. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)